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ABSTRACT
Delayed engraftment remains a limitation of umbilical cord blood (UCB) 
transplantation. We previously showed that inhibition of dipeptidylpeptidase (DPP)-
4 using sitagliptin 600 mg daily was safe with encouraging results on engraftment, 
but inhibition was not sustained. We evaluated the efficacy and feasibility of higher 
doses of sitagliptin to enhance engraftment of UCB in patients with hematological 
cancers. Fifteen patients, median age 41 (range, 18-59) years, received single UCB 
grafts matched at 4 (n=11) or 5 (n=4) of 6 HLA loci with median nucleated cell dose of 
3.5 (range, 2.57-4.57) x107/kg. Sitagliptin 600 mg every 12 hours was administered 
days -1 to +2. All patients engrafted by day 30, with 12 (80%) engrafting by day 21. 
The median time to neutrophil engraftment was 19 (range, 12-30) days. Plasma DPP-4 
activity was better inhibited with a mean residual trough DPP-4 activity of 70%±19%. 
Compared to patients previously treated with 600 mg/day, sitagliptin 600 mg every 
12 hours appeared to improve engraftment, supporting the hypothesis that more 
sustained DPP-4 inhibition is required. In-vivo inhibition of DPP-4 using high-dose 
sitagliptin compares favorably with other approaches to enhance UCB engraftment 
with greater simplicity, and may show synergy in combination with other strategies.
INTRODUCTION
Umbilical cord blood (UCB) is a source of 
hematopoietic stem and progenitor cells (HSPC) 
for transplantation of patients who do not have a 
human leukocyte antigen (HLA)-matched sibling or 
adult unrelated donor. However, delayed neutrophil 
engraftment remains one significant disadvantage of 
UCB transplantation [1, 2]. Several approaches are being 
considered to enhance engraftment of UCB, including 
intraosseous infusion, ex-vivo expansion of hematopoietic 
progenitors, co-transplantation with accessory cells, and 
enhancing homing of HSPC to the bone marrow [1, 3].
The stromal derived factor (SDF)-1α:CXCR4 axis 
plays an important role in homing of stem cells [4], and 
is modulated by the enzyme dipeptidylpeptidase (DPP)-
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4/CD26 [5]. DPP-4 cleaves the N-terminus dipeptide of 
SDF-1α, resulting in a truncated-form of SDF-1 that is 
unable to activate CXCR4; inhibition of DPP-4 enhances 
migration of CD34+ cells [5]. In pre-clinical models, 
DPP-4/CD26 inhibition by ex-vivo pretreatment of donor 
HSPC or systemic inhibition using specific inhibitors 
enhanced engraftment of UCB and murine bone marrow 
cells [6–8]. Recently, we reported the safety of systemic 
DPP-4 inhibition using the clinical inhibitor sitagliptin, 
approved for treatment of type 2 diabetes mellitus, to 
enhance engraftment of single-unit UCB transplantation 
[9]. Although times to neutrophil engraftment were 
encouraging, pharmacodynamic studies suggested the 
schedule of sitagliptin (600 mg daily) was suboptimal in 
producing sustained inhibition of plasma DPP-4, which 
correlated with engraftment [9, 10]. Herein, we present 
results of a prospective trial of 12-hourly dosing of 
sitagliptin to enhance neutrophil engraftment of single-unit 
UCB transplants in patients with high-risk hematological 
malignancies.
RESULTS
Patients and graft characteristics
Fifteen patients were enrolled at Indiana University 
(n=14) and the New York Medical College (n=1) between 
January 2013 and July 2016. One patient subsequently 
found not to have met eligibility because she commenced 
treatment one day earlier than the prescribed 35-day 
interval from previous therapy is included in the analysis. 
The trial was stopped early because of poor accrual. 
Patients and graft characteristics are summarized in Table 
1. All patients received red blood cell-depleted single unit 
UCB grafts. Notably, 11 of the 15 patients received 4/6 
HLA matched UCB units. The median nucleated cell (NC) 
dose pre-freezing was 3.50 (range, 2.57-4.57) x107/kg, and 
the median viable NC dose infused was 2.58 (1.28-3.69) 
x107/kg. Patient characteristics and cell doses infused were 
similar to those included in our pilot study [9].
Engraftment outcome
All 15 patients engrafted by day +30 days following 
transplantation, with 12 patients engrafting by day +21. 
The median time to neutrophil engraftment was 19 (range, 
12-30) days, with a median 100% (range, 95% - 100%) 
donor chimerism at engraftment. Figure 1A shows times to 
neutrophil engraftment of patients treated with sitagliptin 
600 mg every 12 hours on the current study compared 
with the 17 patients also receiving red blood cell-depleted 
cord blood units but treated with 600 mg daily on our 
previous trial where the median time to engraftment was 
21 (range, 13-50) days (P=0.060) [9]. The cumulative 
incidence of platelet recovery to >20x109/l was 46.7% 
(95% confidence interval [CI], 19.3% - 74.0%) by day 
+100, with non-relapse mortality and death from disease 
relapse as competing risks (40.0% [95% CI, 13.3% - 
66.7%]). All engraftment was durable in all patients with 
no secondary graft failures. As an additional comparison, 
we compared the engraftment of patients treated with 
sitagliptin 600 mg every 12 hours on the current study 
with our institutional cohort of 24 consecutive patients 
who received UCB transplants for hematological 
malignancies and a variety of non-malignant disorders 
(other than hemoglobinopathies) without sitagliptin 
between January 2011 and December 2016 (Figure 1B). 
The median age of the latter control patients was 4 (range, 
0.4-21) years with 13 males and 11 females, who received 
UCB grafts that were 4/6 (n=10), 5/6 (n=8), and 6/8 (n=6) 
HLA-matched and containing a median viable NC dose 
of 7.2 (3.0-43.9) x107/kg. As shown, despite more than 
a two and half fold higher median NC dose, engraftment 
was significantly slower (P=0.011) with a median time 
to engraftment of 21.5 (range, days and a cumulative 
incidence of engraftment of 87% (95% CI, 72% - 100%) 
by 100 days post-transplantation.
Toxicity
Grades 3-4 toxicities were expected and similar to 
those previously observed [9]. These included mucositis 
(n=5), self-limiting sinusoidal obstruction syndrome 
(n=1), thrombotic microangiopathy (n=1), and multiorgan 
failure due to sepsis (n=2). Blood glucose levels remained 
essentially unchanged during the sitagliptin dosing period 
and no episodes of hypoglycemia were observed (data 
not shown). Indeed, there were no toxicities that could be 
specifically related to sitagliptin, confirming the safety of 
the drug even at much higher doses than those used for 
diabetes mellitus.
The cumulative incidence of non-relapse mortality at 
6 months was 46.7% (95% CI 19.9%-73.5%), with death 
due to relapse/progression of disease a competing risk. 
Infections, including concurrent adenovirus hepatitis and 
human herpes virus-6 (n=1), Escherichia coli meningitis 
(n=1), vancomycin-resistant enterococcus sepsis (n=2), 
hospital-acquired pneumonia (n=1), and aspergillus 
infection (n=1) were causes of death in 7 patients within 
the first 180 days, with an additional patient dying on day 
+217 from Stenotrophomonas maltophila sepsis. Non-fatal 
cytomegalovirus viremia and herpes simplex stomatitis 
occurred in 4 and 2 patients, respectively. Only one patient 
developed acute GvHD of the skin, clinical grade 1, during 
tapering of immunosuppression drugs, which promptly 
resolved with topical corticosteroid treatment.
Plasma DDP-4 activity
The plasma DPP-4 activity was measured at baseline 
and after dosing, and levels were expressed as residual 
activity as a percentage of baseline (Figure 2). Maximal 
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inhibition of plasma DPP-4 activity occurred at 2-4 hours 
after dosing. The mean (± standard error) plasma DPP-4 
activity at 4 hours after dosing was 56%±16% of baseline. 
Inhibition of plasma DPP-4 was better sustained through 
the dosing interval, with mean residual trough DPP-4 
activity of 70%±19%. The median area under the total 
percent residual DPP-4 activity versus time curve (AUCA) 
for the dosing period was 3,130 (range, 2,004-4,636) 
h*activity, which was significantly lower than that seen in 
our previous trial using 600 mg sitagliptin daily (median 
5,169 [range, 2,932-7,530] h*activity; P=0.000013) [9]. 
There was no correlation between maximal inhibition 
of plasma DPP-4, mean trough levels of DPP-4 activity, 
or AUCA and engraftment in the current trial (result not 
shown).
DISCUSSION
Cell dose is an important determinant of engraftment 
and long-term outcomes following UCB transplantation 
[11, 12]. This has led to use of double-unit UCB grafts 
such that double-unit UCB transplants have exceeded 
those using single UCB units in recent years [13], without 
definitive proof of benefit. A recent randomized trial 
comparing single- versus double-unit UCB transplants 
did not shown enhanced engraftment or improvement in 
Table 1: Patient and graft characteristics
All Patients
(N=15)
Age, median (range) years 41 (18-59)




  CR1 7
  CR3 1
  Primary refractory 2
 ALL
  CR1 2
  Primary refractory 1
 MDS, therapy-related 1
 DLBCL, Relapsed and refractory 1
Number of prior chemotherapy cycles, median (range) 3 (1-10)
Days from diagnosis to transplant, median (range) 156 (87-1234)
HLA-match, n
 5 of 6 4
 4 of 6 11
UCB graft characteristics:
 Pre-freeze NC, median (range) (x107/kg) 3.50 (2.57-4.57)
 Post-thaw viable NC, median (range) (x107/kg) 2.58 (1.28-3.69)
 Post-thaw viable cell recovery, median (range) (%) 72 (47-80)
 Post-thaw CD34+ cells, median (range) (x105/kg) 2.5 (1.0-7.0)
 CFU, median (range) (x104/kg) 2.3 (1.2-7.0)
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell 
lymphoma; MDS, myelodysplastic syndrome; CR, complete remission; NC, nucleated cell count; CFU, colony forming 
units.
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Figure 1: Neutrophil engraftment. (A) Cumulative incidence of neutrophil engraftment comparing patients receiving sitagliptin 600 
mg every 12 hours (n=15) in the current trial with also those receiving 600 mg sitagliptin once daily and red blood cell-depleted UCB units, 
previously reported (n=17).9 (B) Cumulative incidence of neutrophil engraftment comparing patients receiving sitagliptin 600 mg every 12 
hours (n=15) in the current trial with an institutional control of 24 patients receiving UCB transplants without sitagliptin during a similar 
time interval (see text for detail).
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treatment-related mortality, relapse, or overall survival 
following double-unit UCB transplants [14]; the authors 
concluding that single-unit UCB transplants remain a 
standard of care. We focused on enhancing engraftment of 
single-unit UCB transplants, as we felt this was the best 
way to definitively investigate the potential efficacy of 
DPP-4 inhibition.
The observed kinetics of engraftment in this 
trial compare quite favorably with other reports where 
comparable doses and degree of human leukocyte antigen 
(HLA)-mismatching between UCB unit and recipient were 
used, as well with other approaches tested to enhance 
engraftment [15–19], where delays in engraftment still 
occurs in a proportion of patients and primary graft failure 
remains problematic. Furthermore, many of the reported 
approaches to enhance engraftment remain complex, 
require ex-vivo manipulation, and are costly, presenting 
economic concerns [20], and may be prohibitive for 
some centers. In our current trial, all patients engrafted 
neutrophils within 30 days, and 12 of the 15 (80%) patients 
engrafted before day 21. No graft failures were observed. 
The higher dose (600 mg twice daily) of sitagliptin used 
in this trial produced more sustained inhibition of plasma 
DPP-4, with a median AUCA of 3,130 (range, 2,004-
4,636) h*activity, significantly lower than that seen in our 
previous trial using 600 mg sitagliptin daily (median 5,169 
[range, 2,932-7,530] h*activity; P=0.000013) [9]. This 
may have accounted for the faster engraftment kinetics 
observed compared to our previously reported pilot trial 
where plasma DPP-4 inhibition was not sustained with 
only 600 mg daily of sitagliptin despite similar TNC 
(median 3.5x107/kg vs 3.61x107/kg, P=0.28) and similar 
CD34 (median 2.6x104/kg vs 1.0x104/kg, P=0.27) doses 
used in patients also receiving red blood cell-depleted 
UCB units [9], supporting the hypothesis that more 
sustained DPP-4 inhibition may be required for enhanced 
engraftment. Unlike in our previously reported study [9], 
residual AUCA did not correlate with engraftment kinetics 
in the current study. However, we do not believe that this 
is necessarily contradictory as it is possible that once 
below a threshold of residual DPP-4 activity is reached by 
multiple daily dosing of sitagliptin, further improvement 
in the speed of engraftment may not be observed. Of note, 
despite more than a two and a half fold lower infused 
NC dose, the engraftment kinetics of patients treated 
on the current study were also significantly faster than 
an institutional cohort of 24 consecutive patients who 
received UCB transplants without sitagliptin during the 
same time interval. As DPP-4 also decreases GM-CSF, 
G-CSF, interleukin-3 and erythropoietin activities, and 
inhibition/deletion of DPP-4 enhances their activities and 
hematopoietic recovery in vivo after cytotoxic stress in 
preclinical studies [6], longer administration of sitagliptin 
may further enhance engraftment.
Figure 2: Plasma DPP-4 activity. DPP-4 activity following the first following dose of sitagliptin (started on day -1) shown as 
percentages of baseline, comparing the residual activity in patients treated with sitagliptin 600 mg every 12 hours on the current study with 
those receiving sitagliptin 600 mg once daily (black curve) and red blood cell depleted UCB transplants, previously reported (red curve).9 
Times of sitagliptin administration are indicated by “X” at the bottom of the figure.
*Indicate trough levels.
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The higher dose of sitagliptin was well tolerated. 
Overall, grades 3-4 toxicities were expected and similar 
to previously observed [9]. Specifically, there were 
no episodes of hypoglycemia or toxicity that could be 
specifically related to sitagliptin, supporting the safety 
of the drug when administered at much higher doses 
than those used for diabetes mellitus. Despite earlier 
neutrophil recovery, however, infections remained the 
commonest cause of death. Because of the small number 
of patients included, it is not possible to determine if 
sitagliptin increased the risk of infection. However, 
preliminary observations from an ongoing phase II trial 
(NCT02683525) testing sitagliptin for prevention of graft-
versus-host disease following peripheral blood stem cell 
transplantation from matched related and unrelated donors 
do not suggest that in-vivo DPP-4 inhibition increases 
the risk of infections (unpublished). Further, our use of 
ATG in the current trial may have also contributed to the 
high incidence of infections observed. Notwithstanding, 
infections are a recognized problem early following UCB 
transplantation due to delayed immune recovery [21], and 
highlight the need to improve immune function beyond 
neutrophil engraftment.
A limitation of our current study is the small number 
of patients treated. Indeed, the trial failed to meet its 
accrual goal, in part reflecting the reluctance of clinicians 
to use single UCB units in adults despite the lack of 
proven benefit of double UCB units [14]. Importantly, 
the primary endpoint (engraftment by day +30) satisfied 
success criteria of the first stage of the trial, and the 
conditional probability that the null hypothesis would be 
rejected if the study was continued to full planned accrual 
is greater than 99%.
Overall, our results indicate that systemic DPP-
4 inhibition using high-dose sitagliptin given every 
12-hourly enhances engraftment of single-unit UCB 
transplants, and may offer additional benefits over other 
strategies in terms of simplicity and lower cost. It is 
also possible that other strategies may be potentially 
synergistic with in vivo DPP-4 inhibition. In particular, 
PGE2 treatment of donor cells combined with systemic 
DPP-4 inhibition may be synergistic [22], and also PGE2 
induces and maintains naïve and memory CD8+ T cells 




Eligible patients were aged 18-59 years, had acute 
myeloid (AML) or lymphoblastic leukemia (ALL), high-
risk myelodysplasia, or relapsed chemotherapy-refractory 
aggressive non-Hodgkin’s lymphoma, Karnofsky 
performance status ≥70%, adequate organ function, and 
did not have a readily available HLA-matched sibling or 
volunteer unrelated donor. Patients with diabetes mellitus 
requiring insulin or oral hypoglycemic agents, and those 
with a history of pancreatitis, symptomatic cholelithiasis, 
or a history hypersensitivity to sitagliptin were excluded. 
Other eligibility criteria were as previously described [9]. 
The trial was approved by the institutional review boards 
of Indiana University and New York Medical College.
Study treatment and selection of UCB graft
The preparative regimen consisted of high-dose 
melphalan (140 mg/m2 on day -8), thiotepa (10 mg/kg 
actual body weight on day -7), fludarabine (40 mgm2 on 
days -6 to -3), and rabbit anti-thymocyte globulin (1.5 mg/
kg on day -3, and 1.25 mg/kg on days -2 and -1; total 
dose 4 mg/kg) as previously described [24]. Sitagliptin 
(Januvia®; Merck & Co., Inc., Whitehouse Station, NJ) 
600 mg every 12 hours orally was administered on days -1 
through +3; we previously determined in a dose-escalation 
study that this dose and schedule produced more sustained 
plasma DPP-4 inhibition without significant toxicity 
[25]. Graft-versus-host disease (GvHD) prophylaxis 
used sirolimus and tacrolimus as previously described 
[9]. Filgrastim (5 μg/kg/day subcutaneously) was started 
on day +5 and continued until neutrophil recovery. 
Patients received standard antibiotic prophylaxis using 
ciprofloxacin, posaconazole and acyclovir against 
bacterial, mold and viral infections, respectively.
Patients received only single, red blood cell-depleted 
UCB units that were matched at 4 or more of 6 HLA loci, 
and contained >2.5 x107/kg NC before freezing [9]. UCB 
units with the best HLA-match were preferred, and within 
an HLA match level units with greatest NC numbers were 
selected.
Endpoints, sample size and statistical analysis
The primary endpoint of the trial was neutrophil 
engraftment. The trial was designed to demonstrate an 
increase in the proportion of patients engrafting by day 
+30 to ≥70% from an expected 50%, based on results in 
patients transplanted with single unit UCB units of similar 
cell doses and degree of HLA-mismatch [26]. Standard 
definitions of times to neutrophil engraftment and platelet 
recovery were used [9]. Toxicity was graded using the 
NCI Common Terminology Criteria for Adverse Events 
v3.0. Cumulative incidences of neutrophil and platelet 
engraftment were calculated from day 0 until neutrophil 
engraftment and platelet recovery, respectively, with death 
prior to recovery a competing risk. Cumulative incidence 
of non-relapse mortality (NRM) was calculated from day 
0 to death from any cause other than relapse, with death 
due to relapse a competing risk. Pharmacodynamic studies 
of DPP-4 activity and calculation of the area under the 
residual DPP-4 activity versus time curve (AUCA) was 
performed as previously reported [9]. Analyses were 
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performed using SPSS version 22 (IBM Corporation, 
Armonk, NY), and R version 3.3.0 statistical programs.
Abbreviations
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CFU: colony-forming unit; CR: complete remission; 
DLBCL: diffuse large B cell lymphoma; DPP-4: 
dipeptidylpeptidase-4; GvHD: graft-versus-host disease; 
HLA: human leukocyte antigen; HSPC: hematopoietic 
stem and progenitor cell; MDS: myelodysplastic 
syndrome; NC: nucleated cell; SDF-1α: stromal cell 
derived factor-1α; UCB: umbilical cord blood.
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